Oncocyte sells 70% stake in Razor Genomics to Dragon Scientific

Hands Shaking Deal Social

Oncocyte on Wednesday announced the sale of 70% of its wholly-owned subsidiary Razor Genomics to Dragon Scientific.

The deal eliminates an estimated $8 million of annual operating expenses and $13 million of future milestone and development obligations.

The deal reflects Oncocyte’s focus on its product strategy and on reducing its cash burn, the firm's interim CEO Joshua Riggs said in a statement.

It will allow Razor Genomics to continue offering DetermaRx, a molecular stratification test to identify patients with IA-IIA non-squamous non-small cell lung cancer (NSCLC) who may be at low or high risk of having a recurrence. The transaction involves the transfer of all assets and liabilities related to DetermaRx.

Page 1 of 9
Next Page